MA29244B1 - Compositions permettant d'immuniser contre une mycobacterie - Google Patents

Compositions permettant d'immuniser contre une mycobacterie

Info

Publication number
MA29244B1
MA29244B1 MA30124A MA30124A MA29244B1 MA 29244 B1 MA29244 B1 MA 29244B1 MA 30124 A MA30124 A MA 30124A MA 30124 A MA30124 A MA 30124A MA 29244 B1 MA29244 B1 MA 29244B1
Authority
MA
Morocco
Prior art keywords
antigen
compositions
immunizing against
vector expressing
against mycobacteria
Prior art date
Application number
MA30124A
Other languages
English (en)
Inventor
Helen Mcshane
Ansar A Pathan
Adrian Hill
Sarah C Gilbert
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0500102.9A external-priority patent/GB0500102D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of MA29244B1 publication Critical patent/MA29244B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'INVENTION CONCERNE UNE MÉTHODE PERMETTANT DE GÉNÉRER UNE RÉPONSE IMMUNITAIRE DES LYMPHOCYTES T CHEZ UN HÔTE. CETTE MÉTHODE CONSISTE À ADMINISTRER UN VACCIN VECTORISÉ QUI COMPREND UN VECTEUR VIRAL NON RÉPLIQUANT OU À RÉPLICATION ALTÉRÉE EXPRIMANT LE PRODUIT DE TRADUCTION D'UN GÈNE 85A DE L'ANTIGÈNE MYCOBACTÉRIEN. L'INVENTION CONCERNE ÉGALEMENT DES VACCINS VECTORISÉS ET LEURS UTILISATIONS. L'INVENTION CONCERNE ENFIN UNE MÉTHODE PERMETTANT D'INDUIRE UNE RÉPONSE DES LYMPHOCYTES T MÉMOIRE CD8 ET CD4 CONTRE UN ANTIGÈNE AU MOYEN D'UN VECTEUR EXPRIMANT UN ANTIGÈNE OU UN FRAGMENT IMMUNOGÈNE DE CE DERNIER.
MA30124A 2005-01-05 2007-08-03 Compositions permettant d'immuniser contre une mycobacterie MA29244B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500102.9A GB0500102D0 (en) 2005-01-05 2005-01-05 Method for generating a memory t cell response
US64980405P 2005-02-03 2005-02-03

Publications (1)

Publication Number Publication Date
MA29244B1 true MA29244B1 (fr) 2008-02-01

Family

ID=36062509

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30124A MA29244B1 (fr) 2005-01-05 2007-08-03 Compositions permettant d'immuniser contre une mycobacterie

Country Status (16)

Country Link
EP (1) EP1833507B1 (fr)
JP (2) JP2008526823A (fr)
KR (1) KR20070108518A (fr)
AP (1) AP2007004059A0 (fr)
AU (1) AU2006204382B2 (fr)
BR (1) BRPI0606165A2 (fr)
CA (1) CA2592756A1 (fr)
CY (1) CY1111549T1 (fr)
EA (1) EA012436B1 (fr)
HR (1) HRP20110402T1 (fr)
IL (2) IL184414A (fr)
MA (1) MA29244B1 (fr)
MX (1) MX2007008182A (fr)
NZ (1) NZ560468A (fr)
PL (1) PL1833507T3 (fr)
WO (1) WO2006072787A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587507C (fr) * 2004-12-01 2013-11-19 Aeras Global Tb Vaccine Foundation Electroporation of mycobacterium et surexpression d'antigenes dans des mycobacteries
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP2421557B1 (fr) 2009-04-24 2018-12-05 Statens Serum Institut Vaccin contre la tuberculose tb pour prévenir une réactivation
AU2011228996B2 (en) * 2010-03-19 2015-01-29 Lophius Biosciences Gmbh In vitro process for the quick determination of a patient's status relating to infection with Mycobacterium tuberculosis
SG11201500171YA (en) 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
EP3092000A1 (fr) * 2014-01-09 2016-11-16 Transgene SA Fusion d'antigènes mycobactériens hétérooligomères
EP3498866B1 (fr) * 2014-11-25 2026-02-25 Adaptive Biotechnologies Corp. Caractérisation de la réponse immunitaire adaptative à la vaccination ou l'infection au moyen d'un séquençage de répertoire immunitaire
RU2665817C1 (ru) * 2017-10-25 2018-09-04 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Вакцина рекомбинантная противотуберкулезная и адъювант для нее
EP3937967A4 (fr) 2019-03-14 2022-12-14 Sanford Burnham Prebys Medical Discovery Institute Peptides nanomolaires et dérivés pour moduler de manière différentielle les récepteurs de l'éphrine

Also Published As

Publication number Publication date
KR20070108518A (ko) 2007-11-12
IL184414A (en) 2012-01-31
NZ560468A (en) 2010-05-28
IL217235A0 (en) 2012-01-31
HRP20110402T1 (hr) 2011-07-31
AP2007004059A0 (en) 2007-08-31
EA012436B1 (ru) 2009-10-30
AU2006204382A1 (en) 2006-07-13
CY1111549T1 (el) 2015-08-05
PL1833507T3 (pl) 2011-08-31
AU2006204382B2 (en) 2011-05-12
EP1833507B1 (fr) 2011-03-16
WO2006072787A1 (fr) 2006-07-13
BRPI0606165A2 (pt) 2009-06-02
CA2592756A1 (fr) 2006-07-13
EP1833507A1 (fr) 2007-09-19
JP2008526823A (ja) 2008-07-24
EA200701440A1 (ru) 2008-02-28
JP2013010775A (ja) 2013-01-17
IL184414A0 (en) 2007-10-31
WO2006072787A8 (fr) 2006-09-14
MX2007008182A (es) 2008-02-19

Similar Documents

Publication Publication Date Title
Wu et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
Mohite et al. Revolutionizing cancer treatment: unleashing the power of viral vaccines, monoclonal antibodies, and proteolysis-targeting chimeras in the new era of immunotherapy
Kedl et al. Epitope dominance, competition and T cell affinity maturation
Wakim et al. Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection
Kallen et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines
Selvapandiyan et al. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis
Stevenson et al. DNA vaccines against cancer come of age
Sewell et al. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7
Pollet et al. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern
Araújo et al. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2
Bivona et al. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine
Rice et al. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines
WO1999042564A3 (fr) Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose
WO2002061113A3 (fr) Vaccin moleculaire superieur a base d'arn autoreplicatif, d'adn suicide ou de vecteur d'adn nu, qui lie un antigene a un polypeptide qui favorise la presentation de l'antigene
CN107810009A (zh) 涉及施用至少一种mRNA构建体的初免‑加强方案
WO2008057235A3 (fr) AUGMENTATION DE L'IMMUNOGÉNICITÉ DES ANTIGÈNES ASSOCIÉS AUX TUMEURS PAR L'ADJONCTION D'ÉPITOPES αGAL
WO2005007673A3 (fr) Peptides immunogenes
Steffensen et al. Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses
Soundarya et al. Current trends in tuberculosis vaccine
CY1111549T1 (el) Συνθεσεις για ανοσοποιηση εναντι μυκοβακτηριδιου
Chiodetti et al. Class-B CpG-ODN formulated with a nanostructure induces type I interferons-dependent and CD4+ T cell-independent CD8+ T-cell response against unconjugated protein antigen
Arabpour et al. ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection
Lee et al. Evaluation of protective efficacy induced by virus-like particles containing a Trichinella spiralis excretory-secretory (ES) protein in mice
Mazumder et al. PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2
MX2007015950A (es) Inmunoterapeuticos multivalentes de transporte y ampliacion para carcinoma.